TLV has published new general guidelines and version 7.0 of its handbook for pharmaceutical reimbursement and pricing applications. TLV’s new general guidelines and application regulations apply from 1 October 2026. For market access teams, this is not a methodological reset. TLV is mainly consolidating existing assessment practice into one framework. Comparator choice, severity assessment and health economic evaluation are described more explicitly but largely reflect current practice.
The practical changes are more specific:
1️⃣ New simplified procedure for established active substances
A new route is introduced for selected new medicines or formulations with an established active substance.
It can be used when there is no clinically relevant comparator within the benefits scheme and there is a medical need in the benefits scheme.
The assessment of reasonable cost then focuses on direct costs, expected sales, gross margin and reasonable profitability.
2️⃣ Reimbursement restriction criteria are now written into the guidelines
TLV says criteria for reimbursement restrictions previously came from decision practice.
They are now described in the general guidelines, using the same criteria TLV has already applied.
3️⃣ Rare-disease criteria move into the main guideline framework
TLV has applied the special criteria for very rare conditions since 2025.
What changes now is not the core principle, but the placement: the criteria are incorporated into the general guidelines.
This makes the criteria easier to reference directly in Swedish access dossiers.
4️⃣ Price-increase criteria are clarified
The previous general advice on price increases is replaced by the new guideline structure.
TLV states that this should not make price increases easier or harder. The aim is clearer visibility of the circumstances TLV considers.
5️⃣ The company handbook is updated
Version 7.0 reflects the new rules and includes an optional template for health economic analyses. You access the latest iteration of TLV’s handbook here
The template is not mandatory, but TLV says it can support more standardised HE submissions.
Which of these changes will have the greatest impact on Swedish launch planning?
